EUVIMEDEUVIMED entdecken
Crossref

Monocyte Backpack Delivery of Engineered MCF‐7 Exosomes for the Treatment of Early Stage Type 1 Diabetes

Ziyang Zhang, Yichuan Ma, Zhengxin Yu, Yan Jin, Ying Yang, Mengmeng Ji, Hua Yang, Guang Jia, Jinchao Zhang, Zhenhua Li iD, Huifang Liu

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.202503453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Ziyang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding, 071002, P. R. China. Hauptthemen laut MEDLINE: Exosomes, Diabetes Mellitus, Type 1, Monocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Science Fund for Creative Research Groups of Nature Science Foundation of Hebei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder characterized by autoimmune‐mediated destruction of pancreatic β‐cells through cytotoxic T lymphocyte infiltration, leading to absolute insulin deficiency. Supplementation of exogenous insulin can't protect remaining β‐cells or address the root autoimmune cause. The emerging therapeutic strategies focus on immunomodulatory approaches, targeting the activation of the programmed death 1/programmed death ligand 1 (PD‐1/PD‐L1) pathway could attenuate T cell‐mediated β‐cell destruction, thereby alleviating inflammation in early‐stage T1DM. However, nonselective PD‐1/PD‐L1 blockade can cause toxicity. Herein, exosomes from PD‐L1 high MCF‐7 cells are utilized, modified with monocyte‐targeting IgG, and have their contents removed via electroporation to eliminate tumorigenicity. Monocytes have the characteristic of targeting inflammatory sites. rExo‐IgG is stably anchored to the monocytes’ membrane through IgG and transported as a backpack of monocytes to the inflammatory sites (pancreas and wounds). In the pancreatic tissue, rExo‐IgG through PD‐1/PD‐L1 pathway, inhibiting their activation and protecting β‐cells. At the site of tissue injury, rExo‐IgG repolarizes macrophages from pro‐inflammatory M1 to anti‐inflammatory M2. It also promotes fibroblast proliferation and migration, enhancing tissue regeneration. This dual‐targeting exosome platform not only exhibits therapeutic efficacy against early‐stage T1DM but also offers a novel strategy for the treatment of diabetic wound healing disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExosomesDiabetes Mellitus, Type 1MonocytesHumansAnimalsMCF-7 CellsMiceFemaleB7-H1 AntigenImmunoglobulin GInsulin-Secreting Cells

Stichwörter der Autor:innen

backpackexosomemonocytetype 1 diabeteswound healing

Substanzen

B7-H1 AntigenImmunoglobulin G

Autor:innen und Institutionen

  • College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding, 071002, P. R. China.
  • College of Chemistry & Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Chemical Biology…
  • Affiliated Hospital of Hebei University, Baoding, 071000, China.
  • The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, P. R. China.

ORCID-Profile: Zhenhua Li

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Science Fund for Creative Research Groups of Nature Science Foundation of Hebei Province
  • Beijing-Tianjin-Hebei Basic Research Cooperation Project
  • Hebei Province Higher Education Science and Technology Research Project
  • Natural Science Foundation of Hebei Province
  • Cross-Disciplinary Project of Hebei University
  • Research and Innovation Team of Hebei University

Zitieren

APA

Zhang, Z., Ma, Y., Yu, Z., Jin, Y., Yang, Y., Ji, M., Yang, H., Jia, G., Zhang, J., Li, Z., & Liu, H. (2026). Monocyte Backpack Delivery of Engineered MCF‐7 Exosomes for the Treatment of Early Stage Type 1 Diabetes. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503453

Vancouver

Zhang Z, Ma Y, Yu Z, Jin Y, Yang Y, Ji M, et al. Monocyte Backpack Delivery of Engineered MCF‐7 Exosomes for the Treatment of Early Stage Type 1 Diabetes. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503453

BibTeX
@article{Zhang2026,
  author = {Zhang, Ziyang and Ma, Yichuan and Yu, Zhengxin and Jin, Yan and Yang, Ying and Ji, Mengmeng and Yang, Hua and Jia, Guang and Zhang, Jinchao and Li, Zhenhua and Liu, Huifang},
  title = {Monocyte Backpack Delivery of Engineered MCF‐7 Exosomes for the Treatment of Early Stage Type 1 Diabetes},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.202503453}
}
Kostenlos starten →